[HTML][HTML] Bromocriptine and insulin sensitivity in lean and obese subjects
L Bahler, HJ Verberne, E Brakema… - Endocrine …, 2016 - ncbi.nlm.nih.gov
Bromocriptine is a glucose-lowering drug, which was shown to be effective in obese
subjects with insulin resistance. It is usually administered in the morning. The exact working …
subjects with insulin resistance. It is usually administered in the morning. The exact working …
Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus
Diabetes is a global health concern that has affected almost 415 million people globally.
Bromocriptine is a dopamine D2 agonist, which is a Food and Drug Administration (FDA) …
Bromocriptine is a dopamine D2 agonist, which is a Food and Drug Administration (FDA) …
Novel treatments for type 2 diabetes
J Seewoodhary, SC Bain - British Journal of General Practice, 2011 - bjgp.org
6 British Journal of General Practice, January 2011 action in the brain. Studies using
bromocriptine in type 2 diabetes have shown improvements in glycaemic control and …
bromocriptine in type 2 diabetes have shown improvements in glycaemic control and …
Effect of bromocriptine on cardiovascular complications associated with metabolic syndrome in fructose fed rats
VS Nade, LA Kawale, UB Todmal… - Indian Journal of …, 2012 - journals.lww.com
Objective: The objective of the present study was to evaluate the effect of bromocriptine on
cardiovascular complications associated with type-2 diabetes mellitus (DM). Materials and …
cardiovascular complications associated with type-2 diabetes mellitus (DM). Materials and …
[HTML][HTML] The dirty dozen of diabetes
S Kalra, R Chawla, SV Madhu - Indian Journal of Endocrinology …, 2013 - journals.lww.com
The ninth player that deserves to be mentioned alongside the Ominous Octet is the
catecholamine family. Dopamine, which is the catecholamine with highest concentration in …
catecholamine family. Dopamine, which is the catecholamine with highest concentration in …
Why does quick‐release bromocriptine decrease cardiac events?
DSH Bell - Diabetes, Obesity and Metabolism, 2011 - Wiley Online Library
A placebo‐controlled prospective safety study of quick‐release bromocriptine in patients
with type 2 diabetes has shown a 40% reduction in cardiovascular events. Possible …
with type 2 diabetes has shown a 40% reduction in cardiovascular events. Possible …
The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the α2-adrenergic receptors in beta cells
JEDL Van Weenen, ET Parlevliet, P Maechler… - Biochemical …, 2010 - Elsevier
Treatment with the dopamine receptor D2 (DRD2) agonist bromocriptine improves metabolic
features in obese patients with type 2 diabetes by a still unknown mechanism. In the present …
features in obese patients with type 2 diabetes by a still unknown mechanism. In the present …
[HTML][HTML] Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review
MT Birhan, TM Ayele, FW Abebe, FN Dgnew - Diabetology & Metabolic …, 2023 - Springer
Abstract Background Type 2 diabetes (T2DM) patients, including those in good glycemic
control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic …
control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic …
Does bromocriptine improve glycemic control of obese type-2 diabetics?
Background: Various oral hypoglycemic agents have already been administered to type-2
diabetic patients to normalize their plasma glucose concentrations but they have not had …
diabetic patients to normalize their plasma glucose concentrations but they have not had …